Recent CLDX Stock Price | CLDX Stock Predictions | |
$22.70 | ![]() +196.92% |
$67.40 |
Recent CLDX Analyst Ratings Breakdown, Making CLDX Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 10 | 10 | 10 | 10 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 2 | 2 | 2 | 2 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 1.33 | 1.33 | 1.33 | 1.33 |
For the CLDX stock predictions from the analysts covering Celldex Therapeutics, Inc., we have collected all of the individual CLDX stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 10 different analysts covering CLDX (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since CLDX stock predictions may vary widely, another useful metric to consider is the median CLDX stock prediction, which represents the price at which half of the analysts
made CLDX stock predictions that were higher and half made CLDX stock predictions that were lower. This makes for a different take on the CLDX stock predictions out there, as compared to average or mean.
And that median across all the individual CLDX stock predictions was: $69.0 as of 2025-02-18.
The very highest of the CLDX stock predictions for one year price target was $90.0, while the very lowest of the CLDX stock predictions in the analyst group was
$44.0 (with a standard deviation of $14.796). Get the latest Zacks research report on CLDX — FREE
Find out: CLDX next earnings date »
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
RGNX Stock Predictions
SCHN Stock Predictions
NBTB Stock Predictions
ANF Stock Predictions
AAT Stock Predictions
RGEN Stock Predictions
HT Stock Predictions
RTRX Stock Predictions
CVX Stock Predictions
![]()
![]() |
![]() ![]() |
![]() ![]() |
![]() ![]() |
![]() Strong Buy (3.67 out of 4) 69th percentile
(ranked higher than approx. 69% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com ![]() |
![]() ![]() |